In combination therapy with anti-VEGF monoclonal antibodies and zoledronic acid, a therapy that deleted TAMs showed higher therapeutic efficacy than anti-VEGF therapy on its own in several different tumor models [130]. Here, VEGFA is linked to neoplasm.